Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia

Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia Shuxia Zhang, Bangxiang Xie, Yanfang Lin, Chunrong Chen, Shu Yang, and 5 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-4476895/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 14 Sep, 2024 Read the published version in Annals of Hematology → Version 1 posted 12 You are reading this latest preprint version Abstract Background The coronavirus disease 2019 (COVID-19)-associated mortality rate of hemophilia patients is similar to that of the general population, but the risk of hospitalization and bleeding is higher. However, the specific impact of this infection on hemophilia patients remains unknown. We aimed to investigate the impact of the pandemic on the infection susceptibility, symptoms, drug use, and social intercourse of patients with hemophilia. Methods A survey was distributed to 265 patients with hemophilia (185 adults and 80 children) in the Fujian hemophilia therapeutic center (Fuzhou City, China) during the COVID-19 pandemic, and data were collected between January 2022 and January 2023. The impacts of SARS-CoV-2 infection on hemophilia symptoms, drug use, and social intercourse of these patients were investigated, and the association between the recovery time and disease conditions was explored in infected patients. Results During the pandemic, compared with adult patients, pediatric patients had significantly reduced social intercourse and outdoor activities because of the fear of contracting COVID-19 (85.0% vs . 66.5%). Bleeding events were also significantly fewer in children than in adults (61.2% vs . 81.1%). The SARS-CoV-2 infection rate was significantly higher in patients living in urban areas than in those living in rural areas (74.3% vs . 53.6%). The duration of achieving symptomatic recovery from COVID-19 was not significantly associated with hemorrhage, type and classification of hemophilia, presence of inhibitors, complications, and vaccination status. Conclusion Having COVID-19 infection did not significantly influence the symptoms and treatments in patients with hemophilia. Pediatric patients had significantly fewer bleeding events than adults. COVID-19 SARS-CoV-2 hemophilia hemorrhage coagulation factors Figures Figure 1 Background Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was declared as a pandemic by the World Health Organization on March 11, 2020. On May 5, 2023, the World Health Organization officially announced that the COVID-19 pandemic was no longer a global health emergency [ 1 , 2 ]. However, the infection of SARS-CoV-2 has resulted in millions of deaths worldwide and seriously threatened human health in the last 3 years. Studies have shown that COVID-19-related death is significantly associated with chronic diseases like diabetes, hypertension, cardiovascular disease, cerebrovascular disease, and chronic kidney disease [ 3 ]. Compared with patients without cancer, those with cancer, particularly those with hematologic malignancies, are at higher risks of SARS-CoV-2 infection and poorer prognoses [ 4 , 5 ]. Notably, SARS-CoV-2 infection can result in immune dysregulation and can also affect hemostasis. Research findings suggest that the COVID-19-related mortality rate of patients with hemophilia is comparable to that of the general population; however, the former show higher risks of hospitalization and bleeding, particularly gastrointestinal bleeding [ 6 ]. Furthermore, patients with concurrent major bleeding also exhibit elevated levels of D-dimer, higher levels of fibrinogen degradation products, reduced levels of fibrinogen, and prolonged PT and APTT [ 7 ]. However, the impact of COVID-19 on the treatment and prognoses of patients with hemophilia have not been extensively investigated. Hemophilia A and B are rare congenital recessive X-linked disorders which are caused by the deficiency of coagulation factor VIII (FVIII) or IX (FIX), and these diseases almost exclusively affect males. The major clinical manifestation is recurrent joint and muscle bleeding, and patients require long-term coagulation factor replacement therapy to reduce bleeding and prevent joint deformity [ 8 ]. In some rare cases, hemophilia can even induce intracranial or visceral hemorrhage, thus threatening the lives of patients [ 9 ]. The current prevalence of SARS-CoV-2 infection in patients with hemophilia and its impact on the symptoms, social intercourse, and treatment of these patients remain unknown [ 10 ]. The purpose of this study is to analyze the number of patients with hemophilia infected with SARS CoV-2 in our center during the COVID-19 pandemic from January 2022 to January 2023. In addition, the impact of this infection on symptoms, drug use, treatment and social intercourse of patients was investigated, and the association between the recovery time and disease conditions in these patients was explored. This study can provide suggestions for patients with hemophilia to cope with COVID-19 infection and reduce anxiety. Methods Participants and study design The Haemophilia Diagnosis and Treatment Centre of Fujian Medical University Union Hospital provided 24/7 (24 hours a day, 7 days a week) online and offline services. An online interactive questionnaire survey was used to gather the data of hemophilia patients infected with COVID-19 for the aspects of their symptoms, drug use, treatment, and social intercourse. The entire hemophilia patient population followed up in the center was invited to participate in the study. The inclusion criteria were as follows: (1) a diagnosis of hemophilia A or B and (2) FVIII or FIX activity < 40%. An electronic link to the questionnaire was disclosed through a social media platform, “WeChat,” and data were collected from February 01, 2023 to February 07, 2023. Overall, 265 patients consented to participate in this study. The infected individuals tested positive for COVID-19 in a quantitative real-time PCR test. For children younger than 10 years, parents were asked to answer the questions on their behalf. Missing values were avoided by setting the required fields for every question in the online survey. The self-reported data included age, sex, history of chronic diseases, and vaccination status. Meanwhile, we collected and analyzed the data on the following aspects of hemophilia patients: bleeding symptoms, COVID-19 infection, COVID-19 vaccination status, symptoms of COVID-19 infection, the use of various drugs from January 2022 to January 2023, and the impact of the COVID-19 pandemic on social activities. This research was approved by the Ethics Committee of Fujian Medical University Union Hospital (approval No. 2023KY107). The participants were informed that their participation was entirely voluntary and that they could withdraw without providing any justification or answering any survey questions at any time. Participants were guaranteed of the confidentiality of their information. Informed consent statement was provided on the home page of the online survey, which the participants had to read and agree to before starting the questionnaire, and thus, each completed questionnaire was considered to have the participant’s informed consent. Statistical analysis The data described the characteristics of the entire population, including adult and pediatric patients (< 10 years [parent responders] and ≥ 10 years [child responders]). The χ2 test or Fisher exact test was used to describe and compare the symptoms and social intercourses of patients with hemophilia. A P value of < 0.05 indicated a statistically significant difference. The categorical variables were described as frequencies and percentages. Continuous variables are represented as mean ± standard deviation or median (interquartile range). The categorical variables are represented by numbers (%). We used the Shapiro–Wilk test to evaluate the normal distribution of data. All P values were bilateral, and a P value of < 0.05 was considered significant. The difference in the duration of achieving symptomatic recovery from COVID-19 because of the effect of various general characteristics of patients with hemophilia was assessed using the independent-sample t test. All statistical analyses were performed using the SPSS software version 26.0 (IBM Corporation, Armonk, New York, USA). Results Baseline characteristics of patients The social and clinical characteristics of the included participants are shown in Table 1 . The mean age of the 185 adults was 31.83 ± 13.01 years and that of the 80 children was 7.75 ± 4.05 years. The parents answered the questions for children aged <10 years (n = 42). A total of 236 patients (89.1%) had type A hemophilia (including 69 children), whereas 29 patients (10.9%) had type B hemophilia (including 11 children), and hemophilia was severe in 172 patients (65%), including 52 children. Regarding the permanent residence of patients, 140 patients (52.8%) lived in urban areas and 125 patients (47.2%) lived in rural areas. Seventeen patients (6.4%) received treatments with inhibitors; all of them were patients with hemophilia A. Only 80 patients (30.2%) could receive regular preventive treatment, whereas 121 patients (45.7%) were treated as needed, and 46 patients (17.3%) received intermittent prevention; only 1 child aged 3 years received the immune tolerance induction (ITI) treatment. Compared with adult patients, a significantly greater proportion of pediatric patients received regular preventive treatment (45% vs . 28.3%). Only one pediatric patient had comorbidities, which manifested as epilepsy. A total of 59 adult patients had comorbidities, predominantly manifesting as gastrointestinal diseases (10.9%) and hypertension (5.7%). During the COVID-19 pandemic, 191 patients (72.1%) actively isolated themselves at home and reduced social intercourse because of the fear of infection. PCR was used to detect the SARS-CoV-2 nucleic acid in all patients, which showed positive results in 171 patients (64.5%). Only six patients were hospitalized for COVID-19, among whom four (accounting for 66.7% of all hospitalized patients) were unvaccinated (mean hospital stay, 11.25 ± 3.3 days) and two were vaccinated (mean hospital stay, 6 ± 1 days). None of the patients died during the course of the study. Hemophilia symptoms, medication adherence, and social intercourse Table 2 shows the differences in the aspects of bleeding symptoms, medication adherence, and social intercourse between adults and children during the COVID-19 pandemic. In patients with hemophilia A, the incidence rate of bleeding events was significantly higher in adults than in children [80.8% (n = 135) in adults vs . 59.4% (n = 41) in children, P = 0.001], and overall, joint hematoma was the most predominant manifestation (84.4% in adults vs . 63.4% in children). In patients with hemophilia B, the incidence rate of bleeding events did not significantly differ between children and adults. Joint hematoma was the major manifestation in adults (93.3%), whereas only 37.5% of children had joint hematoma. The frequency of bleeding in most patients (82.6% of children and 73.3% of adults) was stable or reduced during the COVID-19 pandemic. In patients with hemophilia A, although the behavioral traits of reduction in social intercourse and active isolation at home to prevent COVID-19 were noted significantly more in children than in adults [85.5% (n = 59) in children vs . 68.9% (n = 115) in adults, P = 0.008], the percentage of patients with COVID-19 infection did not significantly differ between children and adults. The amounts of coagulation factors used during COVID-19 also did not significantly differ between adults and children ( P = 0.483). Similar results were also found for patients with hemophilia B; however, owing to the small number of patients, analyses of statistical significance could not be performed. In terms of disease severity, patients with hemophilia were categorized as having severe (AHF, less than 1%, 172 patients), moderate (AHF, 1% to 5%, 83 patients), or mild hemophilia (AHF, more than 5% up to 40%, 10 patients). The bleeding symptoms, medication adherence, and social intercourse in different groups were compared ( Table 3 ). The findings showed that the occurrence rate of bleeding events, bleeding frequency, amounts of coagulation factors used, and complications did not significantly differ between patients with hemophilia A and hemophilia B. In patients with hemophilia A, social intercourse and the rate of SARS-CoV-2 infection were not associated with the severity of hemophilia. However, in patients with hemophilia B, patients with mild or moderate hemophilia had a higher proportion of SARS-CoV-2 infection than those with severe hemophilia (36.4% vs . 77.8%, P = 0.048); this finding could be explained by patients with severe hemophilia reducing social intercourse and isolating themselves at home more actively than patients with mild or moderate hemophilia (72.7% vs . 50%) because of their more severe fear of COVID-19. Hemophilia symptoms, medication adherence, and social intercourse by patients in urban and rural areas during the COVID-19 pandemic About half of the patients lived in rural areas in Fujian Province, which did not have medical facilities or expertise of the level seen in urban areas. However, the findings of this study revealed no significant difference in bleeding events, bleeding frequency, and amounts of coagulation factors used between patients living in rural and urban areas ( Table 4 ). Further, drugs are freely available for 87.9% of patients in urban areas and 83.2% of patients in rural areas in abundance. Even in the absence of significant differences in social intercourse, the proportion of patients with SARS-CoV-2 infection was still significantly lower in rural areas than in urban areas (53.6%, n = 67 vs . 74.3%, n = 104, P < 0.001), which could be attributed to the relatively smaller population and more effective social distancing in rural areas. Effects of COVID-19 infection on the symptoms of patients with hemophilia In this study, 171 patients (64.5%) contracted the SARS-CoV-2 infection. The effects of COVID-19 on patients with hemophilia are shown in Table 5 . The results showed no significant difference in the severity of hemophilia and the amount of coagulation factor usage between patients who did and did not get COVID-19 infection. Bleeding events were significantly higher in noninfected patients than in infected patients (85.1% vs . 69.6%, P = 0.005). The symptoms of all patients improved, with an average symptomatic recovery period of 6.1 days. The analysis also showed that the lasting time of symptoms after SARS-CoV-2 infection was not significantly associated with bleeding, type and classification of hemophilia, inhibitors, comorbidities, and vaccination ( Fig . 1 ). Discussion Over the last five decades, hemophilia treatment has advanced considerably. Patients with hemophilia can now have almost normal life expectancy and quality of life. However, the sudden pandemic of COVID-19 has posed a challenge to the management of patients with hemophilia [ 10 ]. In this study, we performed follow-up observations in 265 patients with hemophilia during the COVID-19 pandemic, and the results showed that the frequency of bleeding events was stable and unchanged from the pre-pandemic levels. In patients with bleeding, the major manifestation was a joint hematoma, and the rate of bleeding events was significantly higher in adults than in children. Compared with 66.5% of adults, 85% of children reduced social intercourse and actively isolated themselves at home to prevent COVID-19 infection. At the same time, the proportion of individuals receiving preventive treatment was significantly higher in children than in adults. Nevertheless, no difference was found in the proportion of patients infected with SARS-CoV-2 between children and adults. In addition, the amount of coagulation factors used did not significantly differ between adults and children during the COVID-19 pandemic. The initial treatment of patients with hemophilia involved blood-derived coagulation factors, such as purified factors (cryoprecipitate) [ 11 ]. This was followed by the development of recombinant coagulation factors, long-acting coagulation factors, and nonfactor preparations. Genetic therapy has been researched and has shown impressive results in reducing arthropathy and mortality rates in patients with hemophilia [ 9 , 11 , 12 ]. However, the evolution of treatments has been accompanied by the induction of inhibitors, which occurs more in patients with hemophilia A than in those with hemophilia B. Nonfactor treatments, such as ITI treatment [ 13 , 14 ], bypass drug (recombinant activated coagulation factor VII and prothrombin complex) therapy [ 15 ], and emicizumab, are treatments for patients positive for inhibitors [ 16 – 18 ]. In addition, genetic therapies being studied in ongoing clinical trials are also very promising [ 19 ]. In this study, all 17 inhibitor-positive patients had hemophilia A [ 20 , 21 ]. Currently, one patient is receiving ITI treatment in our center. The lockdowns around the world during the COVID-19 pandemic inevitably impact patients with hemophilia. Most data show that lockdowns had little impact on hemophilia symptoms, medication adherence, and mental health of patients. Only one multicenter cross-sectional study performed in Germany investigated the mental health of patients with hereditary bleeding disorders and reported significant differences in the particular thoughts and concerns about COVID-19 in patients and their caregivers [ 22 ]. Thus far, no research has explored the impact of COVID-19 on the aspects of infection, bleeding symptoms, and medication adherence in patients with hemophilia. Our findings suggested that having COVID-19 did not significantly influence the symptoms and treatments in patients with hemophilia. Compared with adults, the pediatric patients had significantly fewer bleeding events. In this study, about half of the patients lived in rural areas, which had poorer economic levels, medical levels, and transportation facilities than urban areas. During the COVID-19 pandemic, our center more actively used remote communication methods like WeChat, telephone, and online teleconferencing to maintain regular contact with patients, particularly those who need more attention and regular follow-ups. In addition, the three-level graded diagnosis and treatment that the Chinese government has been committed to has elevated the treatment level and supported drug allocation in village health centers. Consequently, the findings of this study showed no significant difference in bleeding events, bleeding frequency, and amounts of coagulation factors used between patients in rural and urban areas. In addition, 87.9% of patients in urban areas and 83.2% of patients in rural areas reported that they were capable of purchasing drugs without difficulties in accessibility of drugs. The only difference between patients in rural and urban areas was that the proportion of patients with SARS-CoV-2 infection was significantly lower in rural areas than in urban areas. In this study, 171 patients (64.5%) contracted the SARS-CoV-2 infection. Similar to regular patients with SARS-CoV-2 infection, patients with hemophilia who contracted the SARS-CoV-2 infection also had symptoms of fever, cough, fatigue, sore throat, muscular or body aches, and headache [ 23 , 24 ]. The presence of this infection did not significantly increase the bleeding volume in patients with hemophilia. However, the number of bleeding events was significantly higher in patients without the SARS-CoV-2 infection than in patients with it. Whether this finding can be attributed to the hypercoagulable state of the body after infection with COVID-19 [ 25 , 26 ] needs further verification using big data results. Six patients were hospitalized for pneumonia, including four unvaccinated and two vaccinated patients, with the former having had a significantly longer hospital stay. The average duration of symptoms after SARS-CoV-2 infection was approximately 6.1 days. However, this duration was not significantly associated with bleeding, type and classification of hemophilia, inhibitors, comorbidities, and vaccination status. These findings showed that SARS-CoV-2 infection did not significantly affect the symptoms and treatment of patients with hemophilia. This study has some limitations. We only collected data from one hemophilia center, and COVID-19 is still mutating. In the future, we will further analyze the impact of COVID-19 infection on hemophilia patients by increasing the inclusion of data from multiple centers and incorporating detailed viral subtypes. Therefore, during the pandemic, patients with hemophilia should reduce social activities and take regular prophylaxis. Hemophilia diagnosis and treatment centers can help patients with hemophilia receive better support during disease epidemics using better communication measurements for management and preparation. Conclusions The findings of this study showed that the COVID-19 pandemic did not affect patients with mild or higher grades of hemophilia and had no significant effect on bleeding symptoms, factor therapy levels, and bleeding sites. However, compared with adult patients, pediatric patients had a significantly lower incidence of bleeding events, perhaps because of their reduced social intercourse and outdoor activities. Abbreviations List of abbreviations COVID-19: coronavirus disease 2019 ; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2 ; AHF: anti-hemophilic factor; SD: standard deviation; ITI: immune tolerance induction Declarations Ethics approval and consent to participate: This research was approved by the Ethics Committee of Fujian Medical University Union Hospital (approval No. 2023KY107). The participants were informed that their participation was entirely voluntary and that they could withdraw without providing any justification or answering any survey questions at any time. Consent for publication: Not applicable. Availability of data and materials: The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request. Competing interests: The authors declare that they have no competing interests. Funding: This work was supported by The Natural Science Foundation of Fujian Province of China [2023J01677]; the Construction project of Fujian Medical Center of Hematology [Min201704]; and the National and Fujian Provincial Key Clinical Specialty Discipline Construction Program, P.R.C. Authors' contributions: MH and FYconceived and supervised the study; SZ and YL designed the experiments; CC, XL, SX and JC responsible for the management of haemophilia centers; BX and SY analyzed and interpreted the patient data. SZ was a major contributor in writing the manuscript. All authors read and approved the final manuscript. Acknowledgements: None. References Markov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI et al (2023) The evolution of SARS-CoV-2. Nat Rev Microbiol 21:361–379. 10.1038/s41579-023-00878-2 Hsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T et al (2020) The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature 584:262–267. 10.1038/s41586-020-2404-8 Mehri A, Sotoodeh Ghorbani S, Farhadi-Babadi K, Rahimi E, Barati Z, Taherpour N et al (2023) Risk Factors Associated with Severity and Death from COVID-19 in Iran: A Systematic Review and Meta-Analysis Study. J Intensive Care Med 38:825–837. 10.1177/08850666231166344 Liu Y, Zhang M, Wang X, Yang F, Cao Z, Wang L et al (2023) Dressing Bacteria With a Hybrid Immunoactive Nanosurface to Elicit Dual Anticancer and Antiviral Immunity. Adv Mater 35:e2210949. 10.1002/adma.202210949 Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136:2881–2892. 10.1182/blood.2020008824 Mericliler M, Narayan G (2022) Outcomes of COVID-19 in Adult Males With Hemophilia A: A Propensity Score-Matched Analysis. Cureus 14:e30662. 10.7759/cureus.30662 Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844–847. 10.1111/jth.14768 Srivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW et al (2020) WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 26 Suppl 6:1-158. 10.1111/hae.14046 Haemophilia (2021) Nat Rev Dis Primers 7(1):44. 10.1038/s41572-021-00285-y Hermans C, Weill A, Pierce GF (2020) The COVID-19 pandemic: New global challenges for the haemophilia community. Haemophilia 26:371–372. 10.1111/hae.14001 Peters R, Harris T (2018) Advances and innovations in haemophilia treatment. Nat Rev Drug Discov 17:493–508. 10.1038/nrd.2018.70 Mannucci PM, Tuddenham EG (2001) The hemophilias–from royal genes to gene therapy. N Engl J Med 344:1773–1779. 10.1056/NEJM200106073442307 Malec L, Van Damme A, Chan AKC, Spasova M, Jain N, Sensinger C et al (2023) Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood 141:1982–1989. 10.1182/blood.2022017780 Hart DP, Alamelu J, Bhatnagar N, Biss T, Collins PW, Hall G et al (2021) Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia 27:932–937. 10.1111/hae.14381 Shibeko AM, Woodle SA, Lee TK, Ovanesov MV (2012) Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 120:891–899. 10.1182/blood-2011-11-393371 Rodriguez-Merchan EC, Valentino LA, Emicizumab (2019) Review of the literature and critical appraisal. Haemophilia 25:11–20. 10.1111/hae.13641 Wada H, Matsumoto T, Katayama N (2017) Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 377:2193–2194. 10.1056/NEJMc1712683 Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME et al (2018) Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med 379:811–822. 10.1056/NEJMoa1803550 Yuan Z, Li B, Gu W, Luozhong S, Li R, Jiang S (2022) Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide. J Am Chem Soc 144:20507–20513. 10.1021/jacs.2c09484 Hay CR, DiMichele DM (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 119:1335–1344. 10.1182/blood-2011-08-369132 Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S et al (2016) Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014. Haemophilia. 22 Suppl 1:1–24. 10.1111/hae.12860 von Mackensen S, Halimeh S, Siebert M, Wermes C, Hassenpflug W, Holstein K et al (2020) Impact of COVID-19 pandemic on mental health of patients with inherited bleeding disorders in Germany. Haemophilia 26:e272–e81. 10.1111/hae.14130 Eythorsson E, Helgason D, Ingvarsson RF, Bjornsson HK, Olafsdottir LB, Bjarnadottir V et al (2020) Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study. BMJ 371:m4529. 10.1136/bmj.m4529 Umakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF et al (2020) Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J 96:753–758. 10.1136/postgradmedj-2020-138234 Wadowski PP, Panzer B, Józkowicz A, Kopp CW, Gremmel T, Panzer S et al (2023) Microvascular Thrombosis as a Critical Factor in Severe COVID-19. Int J Mol Sci 24(3). 10.3390/ijms24032492 Stanford S, Roy A, Rea C, Harris B, Ashton A, Mangles S et al (2023) Pilot study to evaluate hypercoagulation and inflammation using rotational thromboelastometry and calprotectin in COVID-19 patients. PLoS ONE 18:e0269738. 10.1371/journal.pone.0269738 Tables Table 1 Sociodemographic and clinical characteristics of the study population Overall population Pediatric patients Adult patients Variables (n = 265) % (n = 80) % (n = 185) % Sex Male 265 100 80 100 185 100 Age Mean ± SD 13.31 ± 12.43 7.75 ± 4.05 31.83 ± 13.01 Type of hemophilia A 236 89.1 69 86.2 167 90.3 B 29 10.9 11 13.8 18 9.7 Severity of hemophilia Severe (AHF < 1%) 172 65 52 65 120 64.9 Moderate (AHF [1; 5] %) 83 31.3 25 31.2 58 31.3 Mild (AHF [5; 40] %) 10 37.7 3 3.8 7 3.8 Type of treatment On demand 121 45.7 26 32.5 95 51.3 Intermittent prophylaxis 46 17.3 12 15 34 18.4 Regular prophylaxis 80 30.2 36 45 44 23.8 ITI 1 0.4 1 1.2 0 0 Other 17 6.4 5 6.3 12 6.5 Residence area Rural (< 2000 inhabitants) 125 47.2 44 55 81 43.8 Urban (≥2000 inhabitants) 140 52.8 36 45 104 56.2 Inhibitor Negative 248 93.6 78 97.5 170 91.9 Positive 17 6.4 2 2.5 15 8.1 Comorbidities Cardiovascular diseases 5 1.9 0 0 5 2.7 Pulmonary diseases 3 1.1 0 0 3 1.6 Digestive diseases 29 10.9 0 0 29 15.7 Hypertension 15 5.7 0 0 15 8.1 Epilepsy 0 0 1 1.2 0 0 Diabetes 7 2.6 0 0 7 3.8 Infected with COVID-19 No 94 35.5 32 40 62 33.5 Yes 171 64.5 48 60 123 66.5 Worried about COVID-19 infection and thus reducing social intercourse (%) No 74 27.9 12 15 62 33.5 Yes 191 72.1 68 85 123 66.5 Abbreviations: AHF, anti-hemophilic factor; SD, standard deviation; ITI, immune tolerance induction Table 2 Difference of symptoms between adults and children with hemophilia during the COVID-19 pandemic Hemophilia A (n = 236) Hemophilia B (n = 29) Pediatric patients Adult patients P value Pediatric patients Adult patients P value (n = 69, 29.2%) (n = 167, 70.8%) (n = 11, 37.9%) (n = 18, 62.1%) Severity of hemophilia Severe (AHF < 1%) 47 (68.1) 114 (68.3) 0.999 5 (45.5) 6 (33.3) － Moderate (AHF [1; 5] %) 19 (27.5) 46 (27.5) 6 (54.5) 12 (66.7) Mild (AHF [5; 40] %) 3 (4.4) 7 (4.2) 0 (0) 0 (0) Bleeding episodes during COVID-19, n (%) No 28 (40.6) 32 (19.2) 0.001 ** 3 (27.3) 3 (16.7) 0.646 Yes 41 (59.4) 135 (80.8) 8 (72.7) 15 (83.3) Hemarthrosis 26 (63.4) 114 (84.4) 3 (37.5) 14 (93.3) Hemorrhagic signs during COVID-19, n (%) No 28 (40.6) 32 (19.2) 0.002 ** 3 (27.3) 3 (16.7) － No change 18 (26.1) 72 (43.1) 6 (54.5) 9 (50) Decrease 11 (15.9) 19 (11.4) 0 (0) 3 (16.7) Increase 12 (17.4) 44 (26.3) 2 (18.2) 3 (16.7) Coagulation factor usage during COVID-19, n (%) No change 36 (52.2) 97 (58.1) 0.483 5 (45.5) 10 (55.6) － Decrease 8 (11.6) 12 (7.2) 2 (18.2) 1 (5.6) Increase 25 (36.2) 58 (34.7) 4 (36.3) 7 (38.8) Infected with COVID-19 No 25 (36.2) 58 (34.7) 0.826 2 (18.2) 4 (22.2) ＞0.999 Yes 44 (63.8) 109 (65.3) 9 (81.8) 14 (77.8) Worried about COVID-19 infection and thus reducing social intercourse (%) No 10 (14.5) 52 (31.1) 0.008 ** 2 (18.2) 10 (55.6) 0.064 Yes 59 (85.5) 115 (68.9) 9 (81.8) 8 (44.4) Abbreviations: AHF, anti-hemophilic factor; *P < 0.05, **P < 0.01, ***P < 0.001 Table 3 Hemophilia symptoms, hemostatic treatment adherence, and social intercourse during COVID-19 Hemophilia type Hemophilia A (n = 236) Hemophilia B (n = 29) Severe Moderate and mild Severe Moderate and mild (n = 161, 68.2%) (n = 75, 31.8%) P value (n = 11, 37.9%) (n = 18, 62.1%) P value Bleeding episodes during COVID-19, n (%) No 39 (24.2) 21 (28.0) 0.535 3 (27.3) 4 (22.2) >0.999 Yes 122 (75.8) 54 (72.0) 8 (72.7) 14 (77.8) Hemarthrosis 99 (81.1) 41 (75.9) 6(75.0) 11(78.6) Hemorrhagic signs during COVID-19, n (%) No 39 (24.2) 21 (28.0) 0.352 3 (27.3) 4 (22.2) － No change 66 (41.0) 24 (32.0) 2 (18.2) 12 (66.7) Decrease 17 (10.6) 13 (17.3) 2 (18.2) 1 (5.5) Increase 39 (24.2) 17 (22.7) 4 (36.4) 1 (5.5) Coagulation factor usage during COVID-19, n (%) No change 92 (57.1) 41 (54.7) 0.059 3 (27.3) 12 (66.7) － Decrease 9 (5.6) 11 (14.7) 1 (9) 2 (11.1) Increase 60 (37.3) 23 (30.6) 7 (63.7) 4 (22.2) Comorbidities No 132 (82.0) 59 (78.7) 0.545 10 (91) 13 (72.3) 0.362 Yes 29 (28.0) 16 (21.3) 1 (9) 5 (17.7) Infected with COVID-19 No 60 (37.3) 23 (30.6) 0.323 7 (63.7) 4 (22.2) 0.048 *# Yes 101 (62.7) 52 (69.4) 4 (36.4) 14 (77.8) Worried about COVID-19 infection and thus reducing social intercourse (%) No 37 (23.0) 25 (33.3) 0.092 3 (27.3) 9 (50) 0.273 Yes 124 (77.0) 50 (66.7) 8 (72.7) 9 (50) Abbreviations: AHF, anti-hemophilic factor; 0.048 *# (Fisher exact test) Table 4 Hemophilia symptoms, hemostatic treatment adherence, and social intercourse in urban and rural areas during COVID-19 Habitation Urban (≥2000 inhabitants) Rural (< 2000 inhabitants) P value (n = 140, 52.8%) (n = 125, 47.2%) Severity of hemophilia Severe (AHF < 1%) 91 (65.0) 81 (64.8) 0.973 Moderate and mild (AHF ≥ 1%) 49 (35.0) 44 (35.2) Bleeding episodes during COVID-19, n (%) No 39 (27.9) 27 (21.6) 0.24 Yes 101 (72.1) 98 (78.4) Hemarthrosis 80 (79.2) 77 (78.6) Hemorrhagic signs during COVID-19, n (%) No 39 (27.9) 27 (21.6) 0.334 No change 58 (41.4) 47 (37.6) Decrease 14 (10.0) 19 (15.2) Increase 29 (20.7) 32 (25.6) Coagulation factor usage during COVID-19, n (%) No change 84 (60.0) 64 (51.2) 0.319 Decrease 12 (8.6) 11 (8.8) Increase 44 (31.4) 50 (40.0) Infected with COVID-19 No 36 (25.7) 58 (46.4) ＜0.001 *** Yes 104 (74.3) 67 (53.6) Worried about COVID-19 infection and thus reducing social intercourse (%) No 42 (30.0) 32 (25.6) 0.425 Yes 98 (70.0) 93 (74.4) Purchase accessibility of the medicine during COVID-19, n (%) Yes 123 (87.9) 104 (83.2) 0.28 No 17 (12.1) 21 (24.8) Abbreviations: AHF, anti-hemophilic factor; * P < 0.05, ** P < 0.01, *** P < 0.001 Table 5 Effects of COVID-19 infection on symptoms of hemophilia patients. Infected with COVID-19 Yes No P value (n = 171, 64.5%) (n = 94, 35.5%) Type of hemophilia A 153 (89.5) 84 (89.3) 0.792 B 18 (10.5) 11 (11.7) Severity of hemophilia Severe (AHF < 1%) 105 (61.4) 67 (71.3) 0.107 Moderate and mild (AHF≥1%) 66 (38.6) 27 (28.7) Hemorrhage sites during COVID-19, n (%) No bleeding 52 (30.4) 14 (14.9) 0.005 ** Hemorrhage 119 (69.6) 80 (85.1) Bleeding sites One site 74 (62.2) 46 (57.5) 0.0634 two sites 31 (26.1) 21 (26.2) more than 3 sites 14 (11.7) 13 (16.3) Hemorrhagic signs during COVID-19, n (%) No 52 (30.4) 14 (14.9) 0.007 ** No change 58 (33.9) 47 (50.0) Decrease 18 (10.5) 15 (16.0) Increase 43 (25.2) 18 (19.1) Coagulation factor usage during COVID-19, n (%) No change 103 (60.2) 45 (47.9) 0.122 Decrease 12 (7.0) 11 (11.7) Increase 56 (32.8) 38 (40.4) Vaccination No 29 (17.0) 22 (23.4) 0.203 Yes 142 (83.0) 72 (76.6) Abbreviations: AHF, anti-hemophilic factor; *P < 0.05, **P < 0.01, ***P < 0.001 Additional Declarations No competing interests reported. Cite Share Download PDF Status: Published Journal Publication published 14 Sep, 2024 Read the published version in Annals of Hematology → Version 1 posted Editorial decision: Revision requested 29 Jul, 2024 Reviews received at journal 29 Jul, 2024 Reviews received at journal 29 Jul, 2024 Reviews received at journal 25 Jul, 2024 Reviewers agreed at journal 11 Jul, 2024 Reviewers agreed at journal 04 Jul, 2024 Reviewers agreed at journal 04 Jul, 2024 Reviewers agreed at journal 14 Jun, 2024 Reviewers invited by journal 06 Jun, 2024 Submission checks completed at journal 04 Jun, 2024 Editor assigned by journal 04 Jun, 2024 First submitted to journal 25 May, 2024 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-4476895","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":314754774,"identity":"03ddb0d3-d84d-4575-bf65-df1747b90cac","order_by":0,"name":"Shuxia Zhang","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Shuxia","middleName":"","lastName":"Zhang","suffix":""},{"id":314754775,"identity":"e881c647-8a96-4336-b528-7e5a4e8b5fb3","order_by":1,"name":"Bangxiang Xie","email":"","orcid":"","institution":"Jianou Integrated traditional Chinese and western medicine hospital，353100","correspondingAuthor":false,"prefix":"","firstName":"Bangxiang","middleName":"","lastName":"Xie","suffix":""},{"id":314754776,"identity":"a090c589-764c-4368-b663-5de6c6c134f9","order_by":2,"name":"Yanfang Lin","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Yanfang","middleName":"","lastName":"Lin","suffix":""},{"id":314754777,"identity":"defb5c1f-39bf-4bb8-8a86-fe4e5aa3c1a2","order_by":3,"name":"Chunrong Chen","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Chunrong","middleName":"","lastName":"Chen","suffix":""},{"id":314754778,"identity":"bbcfbea6-b1f4-4a20-a60f-58ed556d7235","order_by":4,"name":"Shu Yang","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Shu","middleName":"","lastName":"Yang","suffix":""},{"id":314754779,"identity":"9c21ca5c-32d0-4354-8c47-540cde0b62ec","order_by":5,"name":"Shujuan Xu","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Shujuan","middleName":"","lastName":"Xu","suffix":""},{"id":314754780,"identity":"20afe66e-9275-403c-90a6-fa9e2e2a9d68","order_by":6,"name":"Jing Chen","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Jing","middleName":"","lastName":"Chen","suffix":""},{"id":314754781,"identity":"6b2bb62c-99d1-45ba-90f1-6c97009cbe8f","order_by":7,"name":"Xin Li","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Xin","middleName":"","lastName":"Li","suffix":""},{"id":314754782,"identity":"5203d199-b10f-4eb3-80ff-760354ff140b","order_by":8,"name":"Feng’e Yang","email":"","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":false,"prefix":"","firstName":"Feng’e","middleName":"","lastName":"Yang","suffix":""},{"id":314754783,"identity":"787a16e6-3229-4e70-96b1-2b3ca61912c3","order_by":9,"name":"Meijuan Huang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA00lEQVRIiWNgGAWjYBACAwjFxsPP33zgwIcfJGiRkZxxLPHgzB7itTDYGDTkGB/mYCNCi7lE8rOHX3P4eAwYznw4zMDDIM8vdgC/FssZaebGstvYeMyZezccLrBgMJw5O4GAw24kmElLArVYNpzdcHgGD0OCwW2CWtK/gbUYHMh5cJiHjSgtOWaSHyFaGIjUcuZNmTQjUAswkA2AgSxBhF+Op2+T/LntmD0wKh9/+PDDRp5fmoAWEGDmYTgGY0sQVg4CjD8YaohTOQpGwSgYBSMTAABrp0avew0wBgAAAABJRU5ErkJggg==","orcid":"","institution":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital","correspondingAuthor":true,"prefix":"","firstName":"Meijuan","middleName":"","lastName":"Huang","suffix":""}],"badges":[],"createdAt":"2024-05-25 13:08:18","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-4476895/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-4476895/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1007/s00277-024-05992-6","type":"published","date":"2024-09-14T15:58:14+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":58752363,"identity":"1973b3aa-6a72-4d21-ba70-56e3e08ccc11","added_by":"auto","created_at":"2024-06-20 16:13:23","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":364631,"visible":true,"origin":"","legend":"\u003cp\u003eThe relationship between symptom duration and the condition of hemophilia patients after COVID-19 infection. The duration of COVID-19 symptoms in patients with different hemophilia types (A), disease severity (B), inhibitor status (C), comorbidities status (D), vaccination status (E), and bleeding status (F) were compared.\u003c/p\u003e","description":"","filename":"figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-4476895/v1/94060f197af89931b887f9ab.png"},{"id":64619262,"identity":"ff349513-4750-4f37-a676-e54524d495a7","added_by":"auto","created_at":"2024-09-16 16:13:35","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1213081,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-4476895/v1/959fbb33-09da-4ff8-8faf-de3267a585b4.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia ","fulltext":[{"header":"Background","content":"\u003cp\u003eCoronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was declared as a pandemic by the World Health Organization on March 11, 2020. On May 5, 2023, the World Health Organization officially announced that the COVID-19 pandemic was no longer a global health emergency [\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e, \u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e]. However, the infection of SARS-CoV-2 has resulted in millions of deaths worldwide and seriously threatened human health in the last 3 years. Studies have shown that COVID-19-related death is significantly associated with chronic diseases like diabetes, hypertension, cardiovascular disease, cerebrovascular disease, and chronic kidney disease [\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e]. Compared with patients without cancer, those with cancer, particularly those with hematologic malignancies, are at higher risks of SARS-CoV-2 infection and poorer prognoses [\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e, \u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eNotably, SARS-CoV-2 infection can result in immune dysregulation and can also affect hemostasis. Research findings suggest that the COVID-19-related mortality rate of patients with hemophilia is comparable to that of the general population; however, the former show higher risks of hospitalization and bleeding, particularly gastrointestinal bleeding [\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e]. Furthermore, patients with concurrent major bleeding also exhibit elevated levels of D-dimer, higher levels of fibrinogen degradation products, reduced levels of fibrinogen, and prolonged PT and APTT [\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e]. However, the impact of COVID-19 on the treatment and prognoses of patients with hemophilia have not been extensively investigated.\u003c/p\u003e \u003cp\u003eHemophilia A and B are rare congenital recessive X-linked disorders which are caused by the deficiency of coagulation factor VIII (FVIII) or IX (FIX), and these diseases almost exclusively affect males. The major clinical manifestation is recurrent joint and muscle bleeding, and patients require long-term coagulation factor replacement therapy to reduce bleeding and prevent joint deformity [\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e]. In some rare cases, hemophilia can even induce intracranial or visceral hemorrhage, thus threatening the lives of patients [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e].\u003c/p\u003e \u003cp\u003eThe current prevalence of SARS-CoV-2 infection in patients with hemophilia and its impact on the symptoms, social intercourse, and treatment of these patients remain unknown [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. The purpose of this study is to analyze the number of patients with hemophilia infected with SARS CoV-2 in our center during the COVID-19 pandemic from January 2022 to January 2023. In addition, the impact of this infection on symptoms, drug use, treatment and social intercourse of patients was investigated, and the association between the recovery time and disease conditions in these patients was explored. This study can provide suggestions for patients with hemophilia to cope with COVID-19 infection and reduce anxiety.\u003c/p\u003e"},{"header":"Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eParticipants and study design\u003c/h2\u003e \u003cp\u003eThe Haemophilia Diagnosis and Treatment Centre of Fujian Medical University Union Hospital provided 24/7 (24 hours a day, 7 days a week) online and offline services. An online interactive questionnaire survey was used to gather the data of hemophilia patients infected with COVID-19 for the aspects of their symptoms, drug use, treatment, and social intercourse. The entire hemophilia patient population followed up in the center was invited to participate in the study. The inclusion criteria were as follows: (1) a diagnosis of hemophilia A or B and (2) FVIII or FIX activity\u0026thinsp;\u0026lt;\u0026thinsp;40%. An electronic link to the questionnaire was disclosed through a social media platform, \u0026ldquo;WeChat,\u0026rdquo; and data were collected from February 01, 2023 to February 07, 2023.\u003c/p\u003e \u003cp\u003eOverall, 265 patients consented to participate in this study. The infected individuals tested positive for COVID-19 in a quantitative real-time PCR test. For children younger than 10 years, parents were asked to answer the questions on their behalf. Missing values were avoided by setting the required fields for every question in the online survey.\u003c/p\u003e \u003cp\u003eThe self-reported data included age, sex, history of chronic diseases, and vaccination status. Meanwhile, we collected and analyzed the data on the following aspects of hemophilia patients: bleeding symptoms, COVID-19 infection, COVID-19 vaccination status, symptoms of COVID-19 infection, the use of various drugs from January 2022 to January 2023, and the impact of the COVID-19 pandemic on social activities. This research was approved by the Ethics Committee of Fujian Medical University Union Hospital (approval No. 2023KY107). The participants were informed that their participation was entirely voluntary and that they could withdraw without providing any justification or answering any survey questions at any time. Participants were guaranteed of the confidentiality of their information. Informed consent statement was provided on the home page of the online survey, which the participants had to read and agree to before starting the questionnaire, and thus, each completed questionnaire was considered to have the participant\u0026rsquo;s informed consent.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec4\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eThe data described the characteristics of the entire population, including adult and pediatric patients (\u0026lt;\u0026thinsp;10 years [parent responders] and \u0026ge;\u0026thinsp;10 years [child responders]). The χ2 test or Fisher exact test was used to describe and compare the symptoms and social intercourses of patients with hemophilia. A \u003cem\u003eP\u003c/em\u003e value of \u0026lt;\u0026thinsp;0.05 indicated a statistically significant difference. The categorical variables were described as frequencies and percentages. Continuous variables are represented as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;standard deviation or median (interquartile range). The categorical variables are represented by numbers (%). We used the Shapiro\u0026ndash;Wilk test to evaluate the normal distribution of data. All \u003cem\u003eP\u003c/em\u003e values were bilateral, and a \u003cem\u003eP\u003c/em\u003e value of \u0026lt;\u0026thinsp;0.05 was considered significant. The difference in the duration of achieving symptomatic recovery from COVID-19 because of the effect of various general characteristics of patients with hemophilia was assessed using the independent-sample t test. All statistical analyses were performed using the SPSS software version 26.0 (IBM Corporation, Armonk, New York, USA).\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003ch2\u003eBaseline characteristics of patients\u003c/h2\u003e\n\u003cp\u003eThe social and clinical characteristics of the included participants are shown in \u003cstrong\u003eTable 1\u003c/strong\u003e. The mean age of the 185 adults was 31.83 \u0026plusmn; 13.01 years and that of the 80 children was 7.75 \u0026plusmn; 4.05 years. The parents answered the questions for children aged \u0026lt;10 years (n = 42). A total of 236 patients (89.1%) had type A hemophilia (including 69 children), whereas 29 patients (10.9%) had type B hemophilia (including 11 children), and hemophilia was severe in 172 patients (65%), including 52 children. Regarding the permanent residence of patients, 140 patients (52.8%) lived in urban areas and 125 patients (47.2%) lived in rural areas. Seventeen patients (6.4%) received treatments with inhibitors; all of them were patients with hemophilia A. Only 80 patients (30.2%) could receive regular preventive treatment, whereas 121 patients (45.7%) were treated as needed, and 46 patients (17.3%) received intermittent prevention; only 1 child aged 3 years received the immune tolerance induction (ITI) treatment. Compared with adult patients, a significantly greater proportion of pediatric patients received regular preventive treatment (45% \u003cem\u003evs\u003c/em\u003e. 28.3%). Only one pediatric patient had comorbidities, which manifested as epilepsy. A total of 59 adult patients had comorbidities, predominantly manifesting as gastrointestinal diseases (10.9%) and hypertension (5.7%).\u003c/p\u003e\n\u003cp\u003eDuring the COVID-19 pandemic, 191 patients (72.1%) actively isolated themselves at home and reduced social intercourse because of the fear of infection. PCR was used to detect the SARS-CoV-2 nucleic acid in all patients, which showed positive results in 171 patients (64.5%). Only six patients were hospitalized for COVID-19, among whom four (accounting for 66.7% of all hospitalized patients) were unvaccinated (mean hospital stay, 11.25 \u0026plusmn; 3.3 days) and two were vaccinated (mean hospital stay, 6 \u0026plusmn; 1 days). None of the patients died during the course of the study.\u003c/p\u003e\n\u003ch2\u003eHemophilia symptoms, medication adherence, and social intercourse\u003c/h2\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2\u003c/strong\u003e shows the differences in the aspects of bleeding symptoms, medication adherence, and social intercourse between adults and children during the COVID-19 pandemic. In patients with hemophilia A, the incidence rate of bleeding events was significantly higher in adults than in children [80.8% (n = 135) in adults \u003cem\u003evs\u003c/em\u003e. 59.4% (n = 41) in children, \u003cem\u003eP\u003c/em\u003e = 0.001], and overall, joint hematoma was the most predominant manifestation (84.4% in adults \u003cem\u003evs\u003c/em\u003e. 63.4% in children). In patients with hemophilia B, the incidence rate of bleeding events did not significantly differ between children and adults. Joint hematoma was the major manifestation in adults (93.3%), whereas only 37.5% of children had joint hematoma. The frequency of bleeding in most patients (82.6% of children and 73.3% of adults) was stable or reduced during the COVID-19 pandemic.\u003c/p\u003e\n\u003cp\u003eIn patients with hemophilia A, although the behavioral traits of reduction in social intercourse and active isolation at home to prevent COVID-19 were noted significantly more in children than in adults [85.5% (n = 59) in children \u003cem\u003evs\u003c/em\u003e. 68.9% (n = 115) in adults, \u003cem\u003eP\u003c/em\u003e = 0.008], the percentage of patients with COVID-19 infection did not significantly differ between children and adults. The amounts of coagulation factors used during COVID-19 also did not significantly differ between adults and children (\u003cem\u003eP\u003c/em\u003e = 0.483). Similar results were also found for patients with hemophilia B; however, owing to the small number of patients, analyses of statistical significance could not be performed.\u003c/p\u003e\n\u003cp\u003eIn terms of disease severity, patients with hemophilia were categorized as having severe (AHF, less than 1%, 172 patients), moderate (AHF, 1% to 5%, 83 patients), or mild hemophilia (AHF, more than 5% up to 40%, 10 patients). The bleeding symptoms, medication adherence, and social intercourse in different groups were compared (\u003cstrong\u003eTable 3\u003c/strong\u003e). The findings showed that the occurrence rate of bleeding events, bleeding frequency, amounts of coagulation factors used, and complications did not significantly differ between patients with hemophilia A and hemophilia B. In patients with hemophilia A, social intercourse and the rate of SARS-CoV-2 infection were not associated with the severity of hemophilia. However, in patients with hemophilia B, patients with mild or moderate hemophilia had a higher proportion of SARS-CoV-2 infection than those with severe hemophilia (36.4% \u003cem\u003evs\u003c/em\u003e. 77.8%, \u003cem\u003eP\u003c/em\u003e = 0.048); this finding could be explained by patients with severe hemophilia reducing social intercourse and isolating themselves at home more actively than patients with mild or moderate hemophilia (72.7% \u003cem\u003evs\u003c/em\u003e.\u003cem\u003e\u0026nbsp;\u003c/em\u003e50%) because of their more severe fear of COVID-19.\u003c/p\u003e\n\u003ch2\u003eHemophilia symptoms, medication adherence, and social intercourse by patients in urban and rural areas during the COVID-19 pandemic\u003c/h2\u003e\n\u003cp\u003eAbout half of the patients lived in rural areas in Fujian Province, which did not have medical facilities or expertise of the level seen in urban areas. However, the findings of this study revealed no significant difference in bleeding events, bleeding frequency, and amounts of coagulation factors used between patients living in rural and urban areas (\u003cstrong\u003eTable 4\u003c/strong\u003e). Further, drugs are freely available for 87.9% of patients in urban areas and 83.2% of patients in rural areas in abundance. Even in the absence of significant differences in social intercourse, the proportion of patients with SARS-CoV-2 infection was still significantly lower in rural areas than in urban areas (53.6%, n = 67 \u003cem\u003evs\u003c/em\u003e. 74.3%, n = 104, \u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001), which could be attributed to the relatively smaller population and more effective social distancing in rural areas.\u003c/p\u003e\n\u003ch2\u003eEffects of COVID-19 infection on the symptoms of patients with hemophilia\u003c/h2\u003e\n\u003cp\u003eIn this study, 171 patients (64.5%) contracted the SARS-CoV-2 infection. The effects of COVID-19 on patients with hemophilia are shown in \u003cstrong\u003eTable 5\u003c/strong\u003e. The results showed no significant difference in the severity of hemophilia and the amount of coagulation factor usage between patients who did and did not get COVID-19 infection. Bleeding events were significantly higher in noninfected patients than in infected patients (85.1% \u003cem\u003evs\u003c/em\u003e. 69.6%, \u003cem\u003eP\u003c/em\u003e = 0.005). The symptoms of all patients improved, with an average symptomatic recovery period of 6.1 days. The analysis also showed that the lasting time of symptoms after SARS-CoV-2 infection was not significantly associated with bleeding, type and classification of hemophilia, inhibitors, comorbidities, and vaccination (\u003cstrong\u003eFig\u003c/strong\u003e\u003cstrong\u003e. 1\u003c/strong\u003e).\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eOver the last five decades, hemophilia treatment has advanced considerably. Patients with hemophilia can now have almost normal life expectancy and quality of life. However, the sudden pandemic of COVID-19 has posed a challenge to the management of patients with hemophilia [\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e]. In this study, we performed follow-up observations in 265 patients with hemophilia during the COVID-19 pandemic, and the results showed that the frequency of bleeding events was stable and unchanged from the pre-pandemic levels. In patients with bleeding, the major manifestation was a joint hematoma, and the rate of bleeding events was significantly higher in adults than in children. Compared with 66.5% of adults, 85% of children reduced social intercourse and actively isolated themselves at home to prevent COVID-19 infection. At the same time, the proportion of individuals receiving preventive treatment was significantly higher in children than in adults. Nevertheless, no difference was found in the proportion of patients infected with SARS-CoV-2 between children and adults. In addition, the amount of coagulation factors used did not significantly differ between adults and children during the COVID-19 pandemic.\u003c/p\u003e \u003cp\u003eThe initial treatment of patients with hemophilia involved blood-derived coagulation factors, such as purified factors (cryoprecipitate) [\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e]. This was followed by the development of recombinant coagulation factors, long-acting coagulation factors, and nonfactor preparations. Genetic therapy has been researched and has shown impressive results in reducing arthropathy and mortality rates in patients with hemophilia [\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e, \u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e, \u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e]. However, the evolution of treatments has been accompanied by the induction of inhibitors, which occurs more in patients with hemophilia A than in those with hemophilia B. Nonfactor treatments, such as ITI treatment [\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e, \u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e], bypass drug (recombinant activated coagulation factor VII and prothrombin complex) therapy [\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e], and emicizumab, are treatments for patients positive for inhibitors [\u003cspan additionalcitationids=\"CR17\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e]. In addition, genetic therapies being studied in ongoing clinical trials are also very promising [\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e]. In this study, all 17 inhibitor-positive patients had hemophilia A [\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e, \u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e]. Currently, one patient is receiving ITI treatment in our center.\u003c/p\u003e \u003cp\u003eThe lockdowns around the world during the COVID-19 pandemic inevitably impact patients with hemophilia. Most data show that lockdowns had little impact on hemophilia symptoms, medication adherence, and mental health of patients. Only one multicenter cross-sectional study performed in Germany investigated the mental health of patients with hereditary bleeding disorders and reported significant differences in the particular thoughts and concerns about COVID-19 in patients and their caregivers [\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e]. Thus far, no research has explored the impact of COVID-19 on the aspects of infection, bleeding symptoms, and medication adherence in patients with hemophilia. Our findings suggested that having COVID-19 did not significantly influence the symptoms and treatments in patients with hemophilia. Compared with adults, the pediatric patients had significantly fewer bleeding events.\u003c/p\u003e \u003cp\u003eIn this study, about half of the patients lived in rural areas, which had poorer economic levels, medical levels, and transportation facilities than urban areas. During the COVID-19 pandemic, our center more actively used remote communication methods like WeChat, telephone, and online teleconferencing to maintain regular contact with patients, particularly those who need more attention and regular follow-ups. In addition, the three-level graded diagnosis and treatment that the Chinese government has been committed to has elevated the treatment level and supported drug allocation in village health centers. Consequently, the findings of this study showed no significant difference in bleeding events, bleeding frequency, and amounts of coagulation factors used between patients in rural and urban areas. In addition, 87.9% of patients in urban areas and 83.2% of patients in rural areas reported that they were capable of purchasing drugs without difficulties in accessibility of drugs. The only difference between patients in rural and urban areas was that the proportion of patients with SARS-CoV-2 infection was significantly lower in rural areas than in urban areas.\u003c/p\u003e \u003cp\u003eIn this study, 171 patients (64.5%) contracted the SARS-CoV-2 infection. Similar to regular patients with SARS-CoV-2 infection, patients with hemophilia who contracted the SARS-CoV-2 infection also had symptoms of fever, cough, fatigue, sore throat, muscular or body aches, and headache [\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e, \u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e]. The presence of this infection did not significantly increase the bleeding volume in patients with hemophilia. However, the number of bleeding events was significantly higher in patients without the SARS-CoV-2 infection than in patients with it. Whether this finding can be attributed to the hypercoagulable state of the body after infection with COVID-19 [\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e, \u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e] needs further verification using big data results. Six patients were hospitalized for pneumonia, including four unvaccinated and two vaccinated patients, with the former having had a significantly longer hospital stay. The average duration of symptoms after SARS-CoV-2 infection was approximately 6.1 days. However, this duration was not significantly associated with bleeding, type and classification of hemophilia, inhibitors, comorbidities, and vaccination status. These findings showed that SARS-CoV-2 infection did not significantly affect the symptoms and treatment of patients with hemophilia.\u003c/p\u003e \u003cp\u003eThis study has some limitations. We only collected data from one hemophilia center, and COVID-19 is still mutating. In the future, we will further analyze the impact of COVID-19 infection on hemophilia patients by increasing the inclusion of data from multiple centers and incorporating detailed viral subtypes. Therefore, during the pandemic, patients with hemophilia should reduce social activities and take regular prophylaxis. Hemophilia diagnosis and treatment centers can help patients with hemophilia receive better support during disease epidemics using better communication measurements for management and preparation.\u003c/p\u003e"},{"header":"Conclusions","content":"\u003cp\u003eThe findings of this study showed that the COVID-19 pandemic did not affect patients with mild or higher grades of hemophilia and had no significant effect on bleeding symptoms, factor therapy levels, and bleeding sites. However, compared with adult patients, pediatric patients had a significantly lower incidence of bleeding events, perhaps because of their reduced social intercourse and outdoor activities.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cp\u003eList of abbreviations\u003c/p\u003e\n\u003cp\u003eCOVID-19:\u0026nbsp;coronavirus disease 2019 ;\u003c/p\u003e\n\u003cp\u003eSARS-CoV-2: severe acute respiratory syndrome coronavirus 2 ;\u003c/p\u003e\n\u003cp\u003eAHF:\u0026nbsp; \u0026nbsp;anti-hemophilic factor;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eSD:\u0026nbsp;standard deviation;\u0026nbsp;\u003c/p\u003e\n\u003cp\u003eITI: immune tolerance induction\u003c/p\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate:\u0026nbsp;\u003c/strong\u003eThis research was approved by the Ethics Committee of Fujian Medical University Union Hospital (approval No. 2023KY107). The participants were informed that their participation was entirely voluntary and that they could withdraw without providing any justification or answering any survey questions at any time.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication:\u0026nbsp;\u003c/strong\u003eNot applicable.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials:\u0026nbsp;\u003c/strong\u003eThe datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests:\u0026nbsp;\u003c/strong\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding:\u0026nbsp;\u003c/strong\u003eThis work was supported by\u0026nbsp;The Natural Science Foundation of Fujian Province of China [2023J01677]; the Construction project of Fujian Medical Center of Hematology [Min201704]; and the National and Fujian Provincial Key Clinical Specialty Discipline Construction Program, P.R.C.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026apos; contributions:\u0026nbsp;\u003c/strong\u003e MH and FYconceived and supervised the study; SZ and YL designed the experiments; CC, XL, SX and JC responsible for the management of haemophilia centers; BX and SY analyzed and interpreted the patient data. SZ was a major contributor in writing the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAcknowledgements:\u003c/strong\u003e None.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eMarkov PV, Ghafari M, Beer M, Lythgoe K, Simmonds P, Stilianakis NI et al (2023) The evolution of SARS-CoV-2. Nat Rev Microbiol 21:361\u0026ndash;379. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41579-023-00878-2\u003c/span\u003e\u003cspan address=\"10.1038/s41579-023-00878-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHsiang S, Allen D, Annan-Phan S, Bell K, Bolliger I, Chong T et al (2020) The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature 584:262\u0026ndash;267. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41586-020-2404-8\u003c/span\u003e\u003cspan address=\"10.1038/s41586-020-2404-8\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMehri A, Sotoodeh Ghorbani S, Farhadi-Babadi K, Rahimi E, Barati Z, Taherpour N et al (2023) Risk Factors Associated with Severity and Death from COVID-19 in Iran: A Systematic Review and Meta-Analysis Study. J Intensive Care Med 38:825\u0026ndash;837. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1177/08850666231166344\u003c/span\u003e\u003cspan address=\"10.1177/08850666231166344\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLiu Y, Zhang M, Wang X, Yang F, Cao Z, Wang L et al (2023) Dressing Bacteria With a Hybrid Immunoactive Nanosurface to Elicit Dual Anticancer and Antiviral Immunity. Adv Mater 35:e2210949. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/adma.202210949\u003c/span\u003e\u003cspan address=\"10.1002/adma.202210949\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eVijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B et al (2020) Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 136:2881\u0026ndash;2892. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1182/blood.2020008824\u003c/span\u003e\u003cspan address=\"10.1182/blood.2020008824\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMericliler M, Narayan G (2022) Outcomes of COVID-19 in Adult Males With Hemophilia A: A Propensity Score-Matched Analysis. Cureus 14:e30662. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.7759/cureus.30662\u003c/span\u003e\u003cspan address=\"10.7759/cureus.30662\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18:844\u0026ndash;847. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/jth.14768\u003c/span\u003e\u003cspan address=\"10.1111/jth.14768\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSrivastava A, Santagostino E, Dougall A, Kitchen S, Sutherland M, Pipe SW et al (2020) WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 26 Suppl 6:1-158. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/hae.14046\u003c/span\u003e\u003cspan address=\"10.1111/hae.14046\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHaemophilia (2021) Nat Rev Dis Primers 7(1):44. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41572-021-00285-y\u003c/span\u003e\u003cspan address=\"10.1038/s41572-021-00285-y\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHermans C, Weill A, Pierce GF (2020) The COVID-19 pandemic: New global challenges for the haemophilia community. Haemophilia 26:371\u0026ndash;372. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/hae.14001\u003c/span\u003e\u003cspan address=\"10.1111/hae.14001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePeters R, Harris T (2018) Advances and innovations in haemophilia treatment. Nat Rev Drug Discov 17:493\u0026ndash;508. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nrd.2018.70\u003c/span\u003e\u003cspan address=\"10.1038/nrd.2018.70\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMannucci PM, Tuddenham EG (2001) The hemophilias\u0026ndash;from royal genes to gene therapy. N Engl J Med 344:1773\u0026ndash;1779. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJM200106073442307\u003c/span\u003e\u003cspan address=\"10.1056/NEJM200106073442307\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMalec L, Van Damme A, Chan AKC, Spasova M, Jain N, Sensinger C et al (2023) Recombinant factor VIII Fc fusion protein for first-time immune tolerance induction: final results of the verITI-8 study. Blood 141:1982\u0026ndash;1989. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1182/blood.2022017780\u003c/span\u003e\u003cspan address=\"10.1182/blood.2022017780\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHart DP, Alamelu J, Bhatnagar N, Biss T, Collins PW, Hall G et al (2021) Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia 27:932\u0026ndash;937. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/hae.14381\u003c/span\u003e\u003cspan address=\"10.1111/hae.14381\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eShibeko AM, Woodle SA, Lee TK, Ovanesov MV (2012) Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids. Blood 120:891\u0026ndash;899. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1182/blood-2011-11-393371\u003c/span\u003e\u003cspan address=\"10.1182/blood-2011-11-393371\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRodriguez-Merchan EC, Valentino LA, Emicizumab (2019) Review of the literature and critical appraisal. Haemophilia 25:11\u0026ndash;20. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/hae.13641\u003c/span\u003e\u003cspan address=\"10.1111/hae.13641\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWada H, Matsumoto T, Katayama N (2017) Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med 377:2193\u0026ndash;2194. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMc1712683\u003c/span\u003e\u003cspan address=\"10.1056/NEJMc1712683\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME et al (2018) Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med 379:811\u0026ndash;822. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa1803550\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa1803550\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYuan Z, Li B, Gu W, Luozhong S, Li R, Jiang S (2022) Mitigating the Immunogenicity of AAV-Mediated Gene Therapy with an Immunosuppressive Phosphoserine-Containing Zwitterionic Peptide. J Am Chem Soc 144:20507\u0026ndash;20513. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1021/jacs.2c09484\u003c/span\u003e\u003cspan address=\"10.1021/jacs.2c09484\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHay CR, DiMichele DM (2012) The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 119:1335\u0026ndash;1344. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1182/blood-2011-08-369132\u003c/span\u003e\u003cspan address=\"10.1182/blood-2011-08-369132\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S et al (2016) Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014. Haemophilia. 22 Suppl 1:1\u0026ndash;24. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/hae.12860\u003c/span\u003e\u003cspan address=\"10.1111/hae.12860\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003evon Mackensen S, Halimeh S, Siebert M, Wermes C, Hassenpflug W, Holstein K et al (2020) Impact of COVID-19 pandemic on mental health of patients with inherited bleeding disorders in Germany. Haemophilia 26:e272\u0026ndash;e81. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1111/hae.14130\u003c/span\u003e\u003cspan address=\"10.1111/hae.14130\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eEythorsson E, Helgason D, Ingvarsson RF, Bjornsson HK, Olafsdottir LB, Bjarnadottir V et al (2020) Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study. BMJ 371:m4529. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/bmj.m4529\u003c/span\u003e\u003cspan address=\"10.1136/bmj.m4529\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eUmakanthan S, Sahu P, Ranade AV, Bukelo MM, Rao JS, Abrahao-Machado LF et al (2020) Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgrad Med J 96:753\u0026ndash;758. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1136/postgradmedj-2020-138234\u003c/span\u003e\u003cspan address=\"10.1136/postgradmedj-2020-138234\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWadowski PP, Panzer B, J\u0026oacute;zkowicz A, Kopp CW, Gremmel T, Panzer S et al (2023) Microvascular Thrombosis as a Critical Factor in Severe COVID-19. Int J Mol Sci 24(3). \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ijms24032492\u003c/span\u003e\u003cspan address=\"10.3390/ijms24032492\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eStanford S, Roy A, Rea C, Harris B, Ashton A, Mangles S et al (2023) Pilot study to evaluate hypercoagulation and inflammation using rotational thromboelastometry and calprotectin in COVID-19 patients. PLoS ONE 18:e0269738. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1371/journal.pone.0269738\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0269738\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"},{"header":"Tables","content":"\u003cp\u003e\u003cstrong\u003eTable 1\u003c/strong\u003e Sociodemographic and clinical characteristics of the study population\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"724\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003eOverall population\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003ePediatric patients\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003eAdult patients\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eVariables\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e(n = 265)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e(n = 80)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e%\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e(n = 185)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e%\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eSex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e265\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e100\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e100\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e185\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e100\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eAge\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.558011049723757%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.03314917127072%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Mean \u0026plusmn; SD\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"25.552486187845304%\" colspan=\"4\"\u003e\n \u003cp\u003e13.31 \u0026plusmn; 12.43\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.204419889502763%\" colspan=\"4\"\u003e\n \u003cp\u003e7.75 \u0026plusmn; 4.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"22.65193370165746%\" colspan=\"4\"\u003e\n \u003cp\u003e31.83 \u0026plusmn; 13.01\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eType of hemophilia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e236\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e89.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e69\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e86.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e167\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e90.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e10.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e13.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e18\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e9.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eSeverity of hemophilia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Severe (AHF \u0026lt; 1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e172\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e120\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e64.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Moderate (AHF [1; 5] %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e83\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e31.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e25\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e31.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e58\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e31.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Mild (AHF [5; 40] %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e37.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e3.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e3.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eType of treatment\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;On demand\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e121\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e45.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e32.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e95\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e51.3\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Intermittent prophylaxis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e17.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e18.4\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Regular prophylaxis\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e80\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e30.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e23.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;ITI\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e0.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e1.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Other\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e6.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e6.3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e6.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eResidence area\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Rural (\u0026lt; 2000 inhabitants)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e125\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e47.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e55\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e81\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e43.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Urban (\u0026ge;2000 inhabitants)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e140\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e52.8\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e45\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e104\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e56.2\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eInhibitor\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Negative\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e248\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e93.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e78\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e97.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e170\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e91.9\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Positive\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e6.4\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e2.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e8.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eComorbidities\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Cardiovascular diseases\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e1.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e2.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Pulmonary diseases\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e1.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e3\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e1.6\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Digestive diseases\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e10.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e29\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e15.7\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Hypertension\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e5.7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e8.1\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Epilepsy\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e1.2\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;Diabetes\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e2.6\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e0\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e7\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e3.8\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eInfected with COVID-19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e35.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e32\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e62\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e33.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e171\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e64.5\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e123\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e66.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003eWorried about COVID-19 infection and thus reducing social intercourse (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e74\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e27.9\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e62\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e33.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"4.570637119113574%\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.099722991689752%\" colspan=\"2\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"18.698060941828256%\" colspan=\"2\"\u003e\n \u003cp\u003e191\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"6.786703601108033%\" colspan=\"2\"\u003e\n \u003cp\u003e72.1\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"17.31301939058172%\" colspan=\"2\"\u003e\n \u003cp\u003e68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"5.955678670360111%\" colspan=\"2\"\u003e\n \u003cp\u003e85\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.265927977839334%\" colspan=\"2\"\u003e\n \u003cp\u003e123\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.310249307479225%\" colspan=\"2\"\u003e\n \u003cp\u003e66.5\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: AHF, anti-hemophilic factor; SD, standard deviation; ITI, immune tolerance induction\u003cstrong\u003e\u003cbr\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2\u0026nbsp;\u003c/strong\u003eDifference of symptoms between adults and children with hemophilia during the COVID-19 pandemic\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.68982630272953%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"29.280397022332505%\" colspan=\"2\" valign=\"top\" style=\"width: 25.5055%;\"\u003e\n \u003cp\u003eHemophilia A (n = 236)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.188585607940446%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"28.411910669975185%\" colspan=\"2\" valign=\"top\" style=\"width: 24.9214%;\"\u003e\n \u003cp\u003eHemophilia B (n = 29)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.816377171215881%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003ePediatric patients\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003eAdult patients\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003ePediatric patients\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003eAdult patients\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e(n = 69, 29.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e(n = 167, 70.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e(n = 11, 37.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e(n = 18, 62.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003eSeverity of hemophilia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp;Severe (AHF \u0026lt; 1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e47 (68.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e114 (68.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e0.999\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e5 (45.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e6 (33.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e－\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp;Moderate (AHF [1; 5] %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e19 (27.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e46 (27.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e6 (54.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e12 (66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp;Mild (AHF [5; 40] %)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e3 (4.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e7 (4.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"53.90334572490706%\" colspan=\"3\" valign=\"top\" style=\"width: 47.117%;\"\u003e\n \u003cp\u003eBleeding episodes during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e28 (40.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e32 (19.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e0.001\u003csup\u003e**\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e3 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e3 (16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e0.646\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e41 (59.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e135 (80.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e8 (72.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e15 (83.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Hemarthrosis\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e26 (63.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e114 (84.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e3 (37.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e14 (93.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"39.15737298636927%\" colspan=\"2\" valign=\"top\" style=\"width: 34.1695%;\"\u003e\n \u003cp\u003eHemorrhagic signs during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e28 (40.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e32 (19.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e0.002\u003csup\u003e**\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e3 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e3 (16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e－\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e18 (26.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e72 (43.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e6 (54.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e9 (50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e11 (15.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e19 (11.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e0 (0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e3 (16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e12 (17.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e44 (26.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e2 (18.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e3 (16.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"53.90334572490706%\" colspan=\"3\" valign=\"top\" style=\"width: 47.117%;\"\u003e\n \u003cp\u003eCoagulation factor usage during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e36 (52.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e97 (58.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e0.483\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e5 (45.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e10 (55.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e－\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e8 (11.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e12 (7.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e2 (18.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e1 (5.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e25 (36.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e58 (34.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e4 (36.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e7 (38.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003eInfected with COVID-19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e25 (36.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e58 (34.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e0.826\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e2 (18.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e4 (22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e＞0.999\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e44 (63.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e109 (65.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e9 (81.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e14 (77.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"53.90334572490706%\" colspan=\"3\" valign=\"top\" style=\"width: 47.117%;\"\u003e\n \u003cp\u003eWorried about COVID-19 infection and thus reducing social intercourse (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e10 (14.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e52 (31.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e0.008\u003csup\u003e**\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e2 (18.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e10 (55.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e0.064\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"24.65923172242875%\" valign=\"top\" style=\"width: 21.5142%;\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e59 (85.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.745972738537795%\" valign=\"top\" style=\"width: 12.8501%;\"\u003e\n \u003cp\u003e115 (68.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"8.178438661710038%\" valign=\"top\" style=\"width: 7.1065%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.49814126394052%\" valign=\"top\" style=\"width: 12.6554%;\"\u003e\n \u003cp\u003e9 (81.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.002478314745973%\" valign=\"top\" style=\"width: 12.266%;\"\u003e\n \u003cp\u003e8 (44.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.806691449814126%\" valign=\"top\" style=\"width: 6.8144%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: AHF, anti-hemophilic factor; *P \u0026lt; 0.05, **P \u0026lt; 0.01, ***P \u0026lt; 0.001\u003cstrong\u003e\u003cbr\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3\u0026nbsp;\u003c/strong\u003eHemophilia symptoms, hemostatic treatment adherence, and social intercourse during COVID-19\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"824\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003eHemophilia type\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"30.424242424242426%\" colspan=\"2\" style=\"width: 29.9697%;\"\u003e\n \u003cp\u003eHemophilia A (n = 236)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"30.181818181818183%\" colspan=\"2\" style=\"width: 29.9697%;\"\u003e\n \u003cp\u003eHemophilia B (n = 29)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003eSevere\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003eModerate and mild\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003eSevere\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003eModerate and mild\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e(n = 161, 68.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e(n = 75, 31.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e(n = 11, 37.9%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e(n = 18, 62.1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003eBleeding episodes during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e39 (24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e21 (28.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e0.535\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e3 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e4 (22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026gt;0.999\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e122 (75.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e54 (72.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e8 (72.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e14 (77.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Hemarthrosis\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e99 (81.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e41 (75.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e6(75.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e11(78.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003eHemorrhagic signs during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e39 (24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e21 (28.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e0.352\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e3 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e4 (22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e－\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e66 (41.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e24 (32.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e2 (18.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e12 (66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e17 (10.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e13 (17.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e2 (18.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e1 (5.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e39 (24.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e17 (22.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e4 (36.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e1 (5.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003eCoagulation factor usage during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e92 (57.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e41 (54.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e0.059\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e3 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e12 (66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e－\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e9 (5.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e11 (14.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e1 (9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e2 (11.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e60 (37.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e23 (30.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e7 (63.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e4 (22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003eComorbidities\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e132 (82.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e59 (78.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e0.545\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e10 (91)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e13 (72.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e0.362\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e29 (28.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e16 (21.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e1 (9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e5 (17.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003eInfected with COVID-19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e60 (37.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e23 (30.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e0.323\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e7 (63.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e4 (22.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e0.048\u003csup\u003e*#\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e101 (62.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e52 (69.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e4 (36.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e14 (77.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003eWorried about COVID-19 infection and thus reducing social intercourse (%)\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e37 (23.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e25 (33.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e0.092\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e3 (27.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e9 (50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e0.273\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"22.78787878787879%\" style=\"width: 22.6277%;\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"16%\" style=\"width: 15.8875%;\"\u003e\n \u003cp\u003e124 (77.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"14.303030303030303%\" style=\"width: 14.2025%;\"\u003e\n \u003cp\u003e50 (66.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.03030303030303%\" style=\"width: 6.9809%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.030303030303031%\" style=\"width: 14.9247%;\"\u003e\n \u003cp\u003e8 (72.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"15.272727272727273%\" style=\"width: 15.1654%;\"\u003e\n \u003cp\u003e9 (50)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"7.878787878787879%\" style=\"width: 7.8234%;\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: AHF, anti-hemophilic factor; 0.048\u003csup\u003e*#\u0026nbsp;\u003c/sup\u003e(Fisher exact test)\u003cstrong\u003e\u003cbr\u003e\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4\u003c/strong\u003e Hemophilia symptoms, hemostatic treatment adherence, and social intercourse in urban and rural areas during COVID-19\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"725\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003eHabitation\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003eUrban\u0026nbsp;\u003c/p\u003e\n \u003cp\u003e(\u0026ge;2000 inhabitants)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003eRural\u003c/p\u003e\n \u003cp\u003e(\u0026lt; 2000 inhabitants)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e(n = 140, 52.8%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e(n = 125, 47.2%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003eSeverity of hemophilia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp;Severe (AHF \u0026lt; 1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e91 (65.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e81 (64.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e0.973\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp;Moderate and mild (AHF \u0026ge; 1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e49 (35.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e44 (35.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003eBleeding episodes during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e39 (27.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e27 (21.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e0.24\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e101 (72.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e98 (78.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Hemarthrosis\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e80 (79.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e77 (78.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003eHemorrhagic signs during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e39 (27.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e27 (21.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e0.334\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e58 (41.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e47 (37.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e14 (10.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e19 (15.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e29 (20.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e32 (25.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003eCoagulation factor usage during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e84 (60.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e64 (51.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e0.319\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e12 (8.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e11 (8.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e44 (31.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e50 (40.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003eInfected with COVID-19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e36 (25.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e58 (46.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e＜0.001\u003csup\u003e***\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e104 (74.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e67 (53.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003eWorried about COVID-19 infection and thus reducing social intercourse (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e42 (30.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e32 (25.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e0.425\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e98 (70.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e93 (74.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003ePurchase accessibility of the medicine during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e123 (87.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e104 (83.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e0.28\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"40.082644628099175%\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e17 (12.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"24.793388429752067%\"\u003e\n \u003cp\u003e21 (24.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"10.330578512396695%\"\u003e\n \u003cp\u003e \u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: AHF, anti-hemophilic factor; *\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.05, **\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.01, ***\u003cem\u003eP\u003c/em\u003e \u0026lt; 0.001\u0026nbsp;\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 5\u0026nbsp;\u003c/strong\u003eEffects of COVID-19 infection on symptoms of hemophilia patients.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"0\" cellpadding=\"0\" width=\"688\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003eInfected with COVID-19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003eYes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u003cem\u003eP\u003c/em\u003e value\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e(n = 171, 64.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e(n = 94, 35.5%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003eType of hemophilia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;A\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e153 (89.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e84 (89.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e0.792\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;B\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e18 (10.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e11 (11.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003eSeverity of hemophilia\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;Severe (AHF \u0026lt; 1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e105 (61.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e67 (71.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e0.107\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;Moderate and mild (AHF\u0026ge;1%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e66 (38.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e27 (28.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"67.73255813953489%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eHemorrhage sites during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;No bleeding\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e52 (30.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e14 (14.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e0.005\u003csup\u003e**\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;Hemorrhage\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e119 (69.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e80 (85.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Bleeding sites\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; One site\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e74 (62.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e46 (57.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e0.0634\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; two sites\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e31 (26.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e21 (26.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; more than 3 sites\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e14 (11.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e13 (16.3)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"90.84302325581395%\" colspan=\"3\" valign=\"top\"\u003e\n \u003cp\u003eHemorrhagic signs during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e52 (30.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e14 (14.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e0.007\u003csup\u003e**\u003c/sup\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e58 (33.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e47 (50.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e18 (10.5)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e15 (16.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e43 (25.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e18 (19.1)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"67.73255813953489%\" colspan=\"2\" valign=\"top\"\u003e\n \u003cp\u003eCoagulation factor usage during COVID-19, n (%)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; No change\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e103 (60.2)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e45 (47.9)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e0.122\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Decrease\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e12 (7.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e11 (11.7)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp; Increase\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e56 (32.8)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e38 (40.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003eVaccination\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;No\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e29 (17.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e22 (23.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e0.203\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd width=\"41.27906976744186%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;Yes\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"26.453488372093023%\" valign=\"top\"\u003e\n \u003cp\u003e142 (83.0)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"23.11046511627907%\" valign=\"top\"\u003e\n \u003cp\u003e72 (76.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd width=\"9.156976744186046%\" valign=\"top\"\u003e\n \u003cp\u003e\u0026nbsp;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eAbbreviations: AHF, anti-hemophilic factor; *P \u0026lt; 0.05, **P \u0026lt; 0.01, ***P \u0026lt; 0.001\u003c/p\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"annals-of-hematology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"aohe","sideBox":"Learn more about [Annals of Hematology](http://link.springer.com/journal/277)","snPcode":"277","submissionUrl":"https://submission.nature.com/new-submission/277/3","title":"Annals of Hematology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"COVID-19, SARS-CoV-2, hemophilia, hemorrhage, coagulation factors","lastPublishedDoi":"10.21203/rs.3.rs-4476895/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-4476895/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003ch2\u003eBackground\u003c/h2\u003e \u003cp\u003eThe coronavirus disease 2019 (COVID-19)-associated mortality rate of hemophilia patients is similar to that of the general population, but the risk of hospitalization and bleeding is higher. However, the specific impact of this infection on hemophilia patients remains unknown. We aimed to investigate the impact of the pandemic on the infection susceptibility, symptoms, drug use, and social intercourse of patients with hemophilia.\u003c/p\u003e\u003ch2\u003eMethods\u003c/h2\u003e \u003cp\u003eA survey was distributed to 265 patients with hemophilia (185 adults and 80 children) in the Fujian hemophilia therapeutic center (Fuzhou City, China) during the COVID-19 pandemic, and data were collected between January 2022 and January 2023. The impacts of SARS-CoV-2 infection on hemophilia symptoms, drug use, and social intercourse of these patients were investigated, and the association between the recovery time and disease conditions was explored in infected patients.\u003c/p\u003e\u003ch2\u003eResults\u003c/h2\u003e \u003cp\u003eDuring the pandemic, compared with adult patients, pediatric patients had significantly reduced social intercourse and outdoor activities because of the fear of contracting COVID-19 (85.0% \u003cem\u003evs\u003c/em\u003e. 66.5%). Bleeding events were also significantly fewer in children than in adults (61.2% \u003cem\u003evs\u003c/em\u003e. 81.1%). The SARS-CoV-2 infection rate was significantly higher in patients living in urban areas than in those living in rural areas (74.3% \u003cem\u003evs\u003c/em\u003e. 53.6%). The duration of achieving symptomatic recovery from COVID-19 was not significantly associated with hemorrhage, type and classification of hemophilia, presence of inhibitors, complications, and vaccination status.\u003c/p\u003e\u003ch2\u003eConclusion\u003c/h2\u003e \u003cp\u003eHaving COVID-19 infection did not significantly influence the symptoms and treatments in patients with hemophilia. Pediatric patients had significantly fewer bleeding events than adults.\u003c/p\u003e","manuscriptTitle":"Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2024-06-20 16:13:05","doi":"10.21203/rs.3.rs-4476895/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2024-07-30T01:10:36+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-29T16:06:38+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-29T07:59:21+00:00","index":"hide","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2024-07-25T18:07:08+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"259161525367165604367543425350988159921","date":"2024-07-11T14:53:39+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"183105711859445971743358540033730247746","date":"2024-07-04T16:50:59+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"218252867226810402465887187120868159578","date":"2024-07-04T15:49:42+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"84279718612614902780261608285250841996","date":"2024-06-14T07:16:08+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2024-06-06T16:32:15+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2024-06-04T06:34:19+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2024-06-04T06:34:19+00:00","index":"","fulltext":""},{"type":"submitted","content":"Annals of Hematology","date":"2024-05-25T13:01:17+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"annals-of-hematology","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"aohe","sideBox":"Learn more about [Annals of Hematology](http://link.springer.com/journal/277)","snPcode":"277","submissionUrl":"https://submission.nature.com/new-submission/277/3","title":"Annals of Hematology","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"d389022c-07b2-4af9-98c1-96b8c216d1cc","owner":[],"postedDate":"June 20th, 2024","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[],"tags":[],"updatedAt":"2024-09-16T16:05:12+00:00","versionOfRecord":{"articleIdentity":"rs-4476895","link":"https://doi.org/10.1007/s00277-024-05992-6","journal":{"identity":"annals-of-hematology","isVorOnly":false,"title":"Annals of Hematology"},"publishedOn":"2024-09-14 15:58:14","publishedOnDateReadable":"September 14th, 2024"},"versionCreatedAt":"2024-06-20 16:13:05","video":"","vorDoi":"10.1007/s00277-024-05992-6","vorDoiUrl":"https://doi.org/10.1007/s00277-024-05992-6","workflowStages":[]},"version":"v1","identity":"rs-4476895","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-4476895","identity":"rs-4476895","version":["v1"]},"buildId":"qtupq5eGEP_6zYnWcrvyt","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}